作者
MJ Steinhardt, E Wiercinska, M Pham, GU Grigoleit, A Mazzoni, M Da-Via, X Zhou, K Meckel, K Nickel, J Duell, FC Krummenast, S Kraus, C Hopkinson, B Weissbrich, W Müllges, G Stoll, KM Kortüm, H Einsele, H Bonig, L Rasche
发表日期
2020/12
期刊
Journal of Translational Medicine
卷号
18
页码范围
1-6
出版商
BioMed Central
简介
Background
Progressive multifocal leukoencephalopathy is a demyelinating CNS disorder. Reactivation of John Cunningham virus leads to oligodendrocyte infection with lysis and consequent axonal loss due to demyelination. Patients usually present with confusion and seizures. Late diagnosis and lack of adequate therapy options persistently result in permanent impairment of brain functions. Due to profound T cell depletion, impairment of T-cell function and potent immunosuppressive factors, allogeneic hematopoietic cell transplantation recipients are at high risk for JCV reactivation. To date, PML is almost universally fatal when occurring after allo-HCT.
Methods
To optimize therapy specificity, we enriched JCV specific T-cells out of the donor T-cell repertoire from the HLA-identical, anti-JCV-antibody positive family stem cell donor by unstimulated peripheral apheresis [1]. For this, we selected T cells …
引用总数
学术搜索中的文章